Immunome Inc.

IMNM

Immunome Inc.

IMNM

Insider Sentiment (TTM):

Last Purchase:2026-06-05Last Sale:2026-06-25Shares Purchased (TTM):110,468Shares Sold (TTM):611,338

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:94,582,866Shares Outstanding:113,136,836Institutional Ownership Pct.:83.60%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	218	583	653	273	144	258	143	156	165	270	99	91
Available For Sale Securities Debt Securities Curr…	-	-	0	0	124	60	74	85	113	40	39	-
Prepaid Expense And Other Assets Current	18	12	7	7	9	6	4	4	6	4	7	1
Assets Current	538	594	661	280	277	323	221	244	284	313	145	91
Property Plant And Equipment Net	17	17	15	12	11	11	10	7	6	4	2	1
Operating Lease Right Of Use Asset	4	3	3	3	3	4	4	2	3	1	2	0
Deferred Costs	-	-	-	-	-	-	-	-	-	-	-	0
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets Noncurrent	5	5	5	5	4	4	4	3	3	1	0	-
Assets	565	620	683	299	296	343	240	257	296	320	149	93
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	6	6	3	6	5	9	14	4	7	7	3	3
Accrued Liabilities And Other Liabilities	30	22	42	25	18	18	33	26	20	11	8	3
Contract With Customer Liability Current	-	-	0	0	0	4	7	10	13	13	10	17
Liabilities Current	36	27	45	31	23	31	54	40	40	31	22	23
Contract With Customer Liability Noncurrent	-	-	-	-	-	-	-	-	-	2	5	3
Operating Lease Liability Noncurrent	5	4	4	4	4	5	5	2	2	1	1	-
Other Liabilities Noncurrent	-	-	-	-	-	-	-	-	-	-	1	0
Liabilities	40	31	49	35	27	36	59	42	42	34	29	87
Stockholders Equity Inclu…
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,381	1,371	1,362	922	870	865	697	650	642	638	343	136
Accumulated Other Comprehensive Income Loss Net Of…	-	-	0	0	-0	-0	0	0	0	0	0	-
Retained Earnings Accumulated Deficit	-855	-782	-728	-658	-601	-557	-516	-436	-388	-352	-223	-130
Stockholders Equity	525	589	634	264	269	307	181	215	254	286	120	6
Liabilities And Stockholders Equity	565	620	683	299	296	343	240	257	296	320	149	93
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	200
Common Stock Shares Issued	113	113	113	92	87	87	64	60	60	60	43	12
Shares Outstanding	113	113	113	92	87	87	64	60	60	60	43	12

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-18.11%	4.05%	1.72%	-	-	-	-	-	-	-	-	-
2025	14.99%	11.34%	33.38%	-9.08%	10.80%	50.00%	18.84%	40.06%	66.90%	-8.96%	9.38%	0.56%
2024	3.26%	-18.27%	-6.32%	7.12%	4.19%	-8.31%	18.46%	-2.76%	-4.83%	-17.15%	-12.95%	6.53%
2023	-	-	-	-	-	-	-8.88%	25.00%	104.21%	-37.28%	-43.96%	-39.55%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	15.08	21.68	14.69	8.90	12.13	10.49	4.08	6.17	7.12	10.18	6.63	3.96
Quick Ratio	14.56	21.26	14.53	8.67	11.72	10.30	4.00	6.07	6.98	10.07	6.33	3.92
Working Capital	502.74M	566.90M	615.79M	248.48M	254.55M	292.33M	167.03M	204.51M	244.38M	282.56M	122.87M	68.30M
Leverage & Debt
Debt to Equity	0.08	0.05	0.08	0.13	0.10	0.12	0.33	0.20	0.17	0.12	0.24	14.33
Interest Coverage TTM	-16.76	-16.80	-19.12	-20.40	-18.38	-16.75	-23.82	-26.16	-30.17	-44.53	-40.21	-32.10
Debt Ratio	0.07	0.05	0.07	0.12	0.09	0.10	0.25	0.16	0.14	0.11	0.19	0.93
Efficiency & Turnover
Asset Turnover TTM	0.00	0.01	0.02	0.03	0.04	0.03	0.05	0.06	0.06	0.07	0.16	0.16
Per Share Metrics
Diluted EPS TTM	-2.25	-1.99	-2.43	-2.53	-2.44	-2.58	-5.00	-5.07	-4.38	-4.50	-5.38	-1.75
Free Cash Flow Per Share TTM	-1.91	-1.87	-2.36	-1.60	-1.55	-2.03	-2.01	-1.54	-1.09	-0.89	-0.42	0.22
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-5,947.90%	-3,228.83%	-2,419.90%	-1,784.14%	-1,994.30%	-3,382.37%	-3,134.40%	-2,518.49%	-1,871.47%	-781.35%	-222.37%
Net Profit Margin TTM	-	-5,593.85%	-3,059.99%	-2,301.30%	-1,687.08%	-1,875.21%	-3,240.38%	-3,014.59%	-2,435.02%	-1,829.44%	-761.92%	-209.34%
Growth Metrics
Net Revenue Growth (1Y)	-100.00%	-63.29%	-23.23%	-4.44%	16.74%	-13.76%	-35.50%	-0.62%	62.73%	436.51%	-	-
Net Income Growth (1Y)	19.75%	9.50%	-27.50%	-27.05%	-19.12%	-11.60%	174.29%	1,331.14%	904.33%	686.19%	189.48%	-43.23%
EPS Growth (1Y)	-8.02%	-23.14%	-51.33%	-50.07%	-44.29%	-42.62%	-7.18%	190.06%	104.39%	85.82%	76.90%	-43.58%
Valuation Metrics
P/E TTM	-9.44	-11.02	-8.83	-4.62	-3.81	-2.61	-2.13	-2.88	-2.76	-5.48	-1.99	-4.78
P/B TTM	4.57	4.20	2.96	3.90	3.01	1.74	3.44	4.10	2.86	4.45	1.77	16.77
P/S TTM	-	616.26	270.32	106.41	64.28	48.86	68.88	86.90	67.25	100.30	15.15	10.00
Market Cap	2.40B	2.47B	1.88B	1.03B	809.20M	534.43M	622.75M	880.20M	725.23M	1.27B	212.33M	101.89M
Enterprise Value	2.18B	1.89B	1.90B	757.14M	665.11M	276.72M	479.30M	724.53M	559.80M	1.00B	113.55M	11.15M
Calculated Values
Free Cash Flow TTM	-215.82M	-211.04M	-206.12M	-140.64M	-134.72M	-161.35M	-117.97M	-92.59M	-65.53M	-45.80M	-8.40M	2.65M
Net Debt	-217.92M	-582.90M	20.96M	-272.85M	-144.09M	-257.71M	-143.45M	-155.67M	-165.43M	-269.82M	-98.78M	-90.74M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-25Sale

Owner: Lechleider, Robert

Title: Chief Medical Officer

Shares: 55,000

Price/Share: $20.11

Value: $1,106,050.00

Shares Owned: 15,805

Relationship: Officer

Ownership: Direct

2026-06-15Sale

Owner: Rosett, Max

Title: Chief Financial Officer

Shares: 60,000

Price/Share: $18.23

Value: $1,093,800.00

Shares Owned: 54,037

Relationship: Officer

Ownership: Direct

2026-06-05Sale

Owner: Bienaime, Jean Jacques

Title: -

Shares: 10,500

Price/Share: $19.42

Value: $203,910.00

Shares Owned: 32,915

Relationship: Director

Ownership: Direct

2026-06-05Purchase

Owner: Bienaime, Jean Jacques

Title: -

Shares: 10,500

Price/Share: $19.40

Value: $203,700.00

Shares Owned: 43,415

Relationship: Director

Ownership: Direct

2026-05-15Purchase

Owner: Bienaime, Jean Jacques

Title: -

Shares: 5,000

Price/Share: $20.70

Value: $103,500.00

Shares Owned: 43,415

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-25	Lechleider, Robert	Officer	Chief Medical Officer	Direct	Sale	55,000	20.11	$1,106,050.00	15,805	4
2026-06-15	Rosett, Max	Officer	Chief Financial Officer	Direct	Sale	60,000	18.23	$1,093,800.00	54,037	4
2026-06-05	Bienaime, Jean Jacques	Director	-	Direct	Sale	10,500	19.42	$203,910.00	32,915	4
2026-06-05	Bienaime, Jean Jacques	Director	-	Direct	Purchase	10,500	19.40	$203,700.00	43,415	4
2026-05-15	Bienaime, Jean Jacques	Director	-	Direct	Purchase	5,000	20.70	$103,500.00	43,415	4
2026-04-02	Higgins, Jack	Officer	Chief Scientific Officer	Direct	Sale	9,438	21.64	$204,238.32	22,000	4
2026-04-02	Rosett, Max	Officer	Chief Financial Officer	Direct	Sale	65,000	22.20	$1,443,000.00	54,037	4
2026-03-27	Siegall, Clay B	Director,Officer	President and CEO	Direct	Purchase	25,450	19.67	$500,601.50	690,704	4
2026-03-23	Wagenheim, Philip	Director	-	Direct	Sale	28,200	20.65	$582,330.00	341,147	4
2026-03-11	Bienaime, Jean Jacques	Director	-	Direct	Purchase	1,000	21.55	$21,550.00	38,415	4
2025-12-30	Siegall, Clay B	Director,Officer	President and CEO	Direct	Purchase	4,729	21.15	$100,018.35	665,254	4
2025-12-22	Barchas, Isaac	Director	-	Indirect	Sale	383,200	22.03	$8,441,896.00	2,031,181	4
2025-12-19	Tsai, Philip	Officer	Chief Technical Officer	Direct	Purchase	10,000	20.49	$204,900.00	43,300	4
2025-12-19	Siegall, Clay B	Director,Officer	President and CEO	Direct	Purchase	7,278	20.48	$149,053.44	860,525	4
2025-12-18	Siegall, Clay B	Director,Officer	President and CEO	Direct	Purchase	46,511	21.50	$999,986.50	853,247	4
2025-06-03	Bienaime, Jean Jacques	Director	-	Direct	Purchase	5,000	9.38	$46,900.00	36,415	4
2025-03-26	Siegall, Clay B	Director,Officer	President and CEO	Direct	Purchase	137,100	7.29	$999,459.00	806,736	4
2025-03-25	Bienaime, Jean Jacques	Director	-	Direct	Purchase	7,800	7.78	$60,684.00	31,415	4
2025-03-24	Tsai, Philip	Officer	Chief Technology Officer	Direct	Purchase	12,300	8.42	$103,566.00	33,300	4
2025-03-24	Bienaime, Jean Jacques	Director	-	Direct	Purchase	7,000	8.21	$57,470.00	23,615	4
2025-01-31	Siegall, Clay B	Director,Officer	President and CEO	Direct	Purchase	150,000	7.75	$1,162,500.00	669,636	4
2024-11-22	Siegall, Clay B	Director,Officer	President and CEO	Direct	Purchase	33,943	9.78	$331,962.54	519,636	4
2024-11-21	Tsai, Philip	Officer	Chief Technology Officer	Direct	Purchase	21,000	9.43	$198,030.00	21,000	4
2024-11-21	Lechleider, Robert	Officer	Chief Medical Officer	Direct	Purchase	15,805	9.48	$149,831.40	15,805	4
2024-09-19	Rosett, Max	Officer	Chief Financial Officer	Direct	Sale	14,380	16.01	$230,223.80	47,476	4
2024-08-16	Bienaime, Jean Jacques	Director	-	Direct	Purchase	7,000	13.94	$97,580.00	16,615	4
2024-08-15	Higgins, Jack	Officer	Chief Scientific Officer	Direct	Sale	3,524	13.93	$49,089.32	16,000	4
2024-05-21	Siegall, Clay B	Director,Officer	President and CEO	Direct	Purchase	20,434	13.78	$281,580.52	419,636	4
2024-05-21	Bienaime, Jean Jacques	Director	-	Direct	Purchase	2,000	13.57	$27,140.00	9,615	4
2023-10-02	Siegall, Clay B	Director,Officer	President and CEO	Direct	Purchase	169,204	5.91	$999,995.64	319,636	4
2023-10-02	Turner, Bruce	Officer	Chief Strategy Officer	Direct	Purchase	42,300	5.91	$249,993.00	42,300	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

83.60%

Inst. Shares: 94,582,866

Shares Outstanding: 113,136,836

2025-12-31

115.80%

Inst. Shares: 101,155,015

Shares Outstanding: 87,350,956

2025-09-30

89.68%

Inst. Shares: 78,882,489

Shares Outstanding: 87,957,868

2025-06-30

77.51%

Inst. Shares: 67,445,809

Shares Outstanding: 87,010,742

2025-03-31

82.76%

Inst. Shares: 65,719,905

Shares Outstanding: 79,410,354

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	94,582,866	113,136,836	83.60%
2025-12-31	101,155,015	87,350,956	115.80%
2025-09-30	78,882,489	87,957,868	89.68%
2025-06-30	67,445,809	87,010,742	77.51%
2025-03-31	65,719,905	79,410,354	82.76%
2024-12-31	45,121,742	58,639,441	76.95%
2024-09-30	43,005,830	60,205,327	71.43%
2024-06-30	41,064,206	59,936,703	68.51%
2024-03-31	31,909,357	51,544,383	61.91%
2023-12-31	20,171,538	19,843,651	101.65%
2023-09-30	1,724,717	12,202,335	14.13%
2023-06-30	1,515,866	12,197,801	12.43%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Immunome Inc. (IMNM) — SEC Financial Statements & Analysis

Immunome Inc. (IMNM) is a pharmaceutical preparations company, incorporated in DE. Immunome Inc. trades on Nasdaq as: IMNM. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Immunome Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.08x, a Price-to-Sales (P/S) ratio of 616.26x (TTM), a Price-to-Book (P/B) ratio of 4.57x (TTM), at a market cap of $2.40B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.08x
P/S TTM: 616.26x
P/B TTM: 4.57x
Market Cap: $2.40B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Immunome Inc. in?

Immunome Inc. (IMNM) operates in the Pharmaceutical Preparations industry.

What is IMNM's market cap?

Immunome Inc. (IMNM) has a market capitalization of $2.40B as of 2026-06-30.

What exchange does IMNM trade on?

Immunome Inc. (IMNM) trades on the Nasdaq.

Where is Immunome Inc. incorporated?

Immunome Inc. is incorporated in DE.

Immunome Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Immunome Inc. (IMNM) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

Immunome Inc. (IMNM) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.